Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.59
ABT's Cash to Debt is ranked higher than
59% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ABT: 0.59 )
ABT' s 10-Year Cash to Debt Range
Min: 0.05   Max: 1.23
Current: 0.59

0.05
1.23
Equity to Asset 0.54
ABT's Equity to Asset is ranked higher than
64% of the 450 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ABT: 0.54 )
ABT' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.59
Current: 0.54

0.37
0.59
Interest Coverage 16.75
ABT's Interest Coverage is ranked higher than
55% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 234.31 vs. ABT: 16.75 )
ABT' s 10-Year Interest Coverage Range
Min: 4.91   Max: 34.27
Current: 16.75

4.91
34.27
F-Score: 6
Z-Score: 3.74
M-Score: -2.70
WACC vs ROIC
8.53%
9.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 13.04
ABT's Operating margin (%) is ranked higher than
87% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. ABT: 13.04 )
ABT' s 10-Year Operating margin (%) Range
Min: 8.81   Max: 24.91
Current: 13.04

8.81
24.91
Net-margin (%) 10.75
ABT's Net-margin (%) is ranked higher than
87% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. ABT: 10.75 )
ABT' s 10-Year Net-margin (%) Range
Min: 7.64   Max: 27.74
Current: 10.75

7.64
27.74
ROE (%) 11.54
ABT's ROE (%) is ranked higher than
86% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 5.02 vs. ABT: 11.54 )
ABT' s 10-Year ROE (%) Range
Min: 9.93   Max: 43.42
Current: 11.54

9.93
43.42
ROA (%) 6.44
ABT's ROA (%) is ranked higher than
84% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. ABT: 6.44 )
ABT' s 10-Year ROA (%) Range
Min: 4.68   Max: 18.73
Current: 6.44

4.68
18.73
ROC (Joel Greenblatt) (%) 30.40
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. ABT: 30.40 )
ABT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15.3   Max: 89.14
Current: 30.4

15.3
89.14
Revenue Growth (3Y)(%) -15.00
ABT's Revenue Growth (3Y)(%) is ranked higher than
54% of the 344 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. ABT: -15.00 )
ABT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -15   Max: 13.7
Current: -15

-15
13.7
EBITDA Growth (3Y)(%) -21.20
ABT's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ABT: -21.20 )
ABT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30   Max: 31.5
Current: -21.2

-30
31.5
EPS Growth (3Y)(%) -20.40
ABT's EPS Growth (3Y)(%) is ranked higher than
65% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. ABT: -20.40 )
ABT' s 10-Year EPS Growth (3Y)(%) Range
Min: -54   Max: 48.8
Current: -20.4

-54
48.8
» ABT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ABT Guru Trades in Q1 2014

Louis Moore Bacon 10,998 sh (New)
Ray Dalio 17,200 sh (New)
Steven Cohen 156,100 sh (+2676.59%)
Diamond Hill Capital 5,984,714 sh (+93.78%)
George Soros 1,222,181 sh (+25.97%)
Ken Fisher 8,746 sh (+14.4%)
Richard Pzena 6,934,282 sh (+7.9%)
PRIMECAP Management 17,087,028 sh (+5.89%)
John Buckingham 88,280 sh (+2.84%)
Mason Hawkins 13,747,344 sh (+2.25%)
Robert Olstein 182,000 sh (+1.68%)
Jeremy Grantham 16,360,821 sh (+1.28%)
Murray Stahl 34,903 sh (+0.87%)
Dodge & Cox 36,950 sh (+0.05%)
Tom Russo 86,503 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Jeff Auxier 80,490 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Paul Tudor Jones Sold Out
Daniel Loeb Sold Out
Jim Simons Sold Out
Bill Frels 343,865 sh (-2.14%)
Pioneer Investments 2,002,948 sh (-7.03%)
Mario Gabelli 168,487 sh (-14.55%)
» More
Q2 2014

ABT Guru Trades in Q2 2014

Jim Simons 1,503,700 sh (New)
Jean-Marie Eveillard 1,665,688 sh (New)
Paul Tudor Jones 25,430 sh (New)
Ken Fisher 18,027 sh (+106.12%)
Diamond Hill Capital 6,422,284 sh (+7.31%)
Bill Frels 368,808 sh (+7.25%)
Richard Pzena 7,197,691 sh (+3.8%)
Ray Dalio 17,700 sh (+2.91%)
John Buckingham 89,447 sh (+1.32%)
PRIMECAP Management 17,127,063 sh (+0.23%)
Louis Moore Bacon 10,998 sh (unchged)
Robert Olstein 182,000 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Tom Russo 86,503 sh (unchged)
Dodge & Cox 36,898 sh (-0.14%)
Mason Hawkins 13,687,877 sh (-0.43%)
Pioneer Investments 1,990,174 sh (-0.64%)
Jeff Auxier 79,671 sh (-1.02%)
Murray Stahl 34,303 sh (-1.72%)
Mario Gabelli 160,707 sh (-4.62%)
George Soros 932,181 sh (-23.73%)
Jeremy Grantham 11,956,508 sh (-26.92%)
» More
Q3 2014

ABT Guru Trades in Q3 2014

Steven Cohen 200,000 sh (New)
Diamond Hill Capital 7,624,383 sh (+18.72%)
Dodge & Cox 39,628 sh (+7.4%)
Richard Pzena 7,287,523 sh (+1.25%)
John Buckingham 89,801 sh (+0.4%)
Pioneer Investments 1,989,506 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Tom Russo 86,503 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Robert Olstein 182,000 sh (unchged)
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
PRIMECAP Management 17,089,257 sh (-0.22%)
Jeff Auxier 79,371 sh (-0.38%)
Bill Frels 359,970 sh (-2.4%)
Mason Hawkins 12,483,566 sh (-8.8%)
Jean-Marie Eveillard 1,426,919 sh (-14.33%)
George Soros 797,181 sh (-14.48%)
Murray Stahl 29,303 sh (-14.58%)
Jeremy Grantham 10,155,603 sh (-15.06%)
Ken Fisher 11,261 sh (-37.53%)
Mario Gabelli 98,937 sh (-38.44%)
Paul Tudor Jones 8,170 sh (-67.87%)
Jim Simons 144,983 sh (-90.36%)
» More
Q4 2014

ABT Guru Trades in Q4 2014

Ray Dalio 45,000 sh (New)
Jim Simons 859,200 sh (+492.62%)
Ken Fisher 13,828 sh (+22.8%)
Diamond Hill Capital 8,070,717 sh (+5.85%)
PRIMECAP Management 17,638,084 sh (+3.21%)
John Buckingham 90,882 sh (+1.2%)
Robert Bruce 230,915 sh (+0.7%)
Paul Tudor Jones 8,209 sh (+0.48%)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Steven Cohen Sold Out
Jeff Auxier 78,871 sh (-0.63%)
Bill Frels 356,819 sh (-0.88%)
Tom Russo 85,400 sh (-1.28%)
Pioneer Investments 1,959,061 sh (-1.53%)
Robert Olstein 179,000 sh (-1.65%)
Richard Pzena 6,860,439 sh (-5.86%)
Dodge & Cox 37,068 sh (-6.46%)
Jeremy Grantham 9,110,222 sh (-10.29%)
Jean-Marie Eveillard 1,250,956 sh (-12.33%)
George Soros 602,181 sh (-24.46%)
Murray Stahl 21,473 sh (-26.72%)
Mason Hawkins 8,977,941 sh (-28.08%)
Mario Gabelli 65,337 sh (-33.96%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mason Hawkins 2014-12-31 Reduce -28.08%0.79%$39.99 - $46.37 $ 47.379%8977941
George Soros 2014-12-31 Reduce -24.46%0.06%$39.99 - $46.37 $ 47.379%602181
Ray Dalio 2014-12-31 New Buy0.02%$39.99 - $46.37 $ 47.379%45000
Mario Gabelli 2014-12-31 Reduce -33.96%0.01%$39.99 - $46.37 $ 47.379%65337
Ken Fisher 2014-12-31 Add 22.8%$39.99 - $46.37 $ 47.379%13828
Mason Hawkins 2014-09-30 Reduce -8.8%0.26%$41.05 - $43.69 $ 47.3712%12483566
Ray Dalio 2014-09-30 Sold Out 0.01%$41.05 - $43.69 $ 47.3712%0
Mario Gabelli 2014-09-30 Reduce -38.44%0.01%$41.05 - $43.69 $ 47.3712%98937
Ken Fisher 2014-09-30 Reduce -37.53%$41.05 - $43.69 $ 47.3712%11261
Jean-Marie Eveillard 2014-06-30 New Buy0.16%$37.02 - $41 $ 47.3721%1665688
George Soros 2014-06-30 Reduce -23.73%0.11%$37.02 - $41 $ 47.3721%932181
Ken Fisher 2014-06-30 Add 106.12%$37.02 - $41 $ 47.3721%18027
Daniel Loeb 2014-03-31 Sold Out 2.1%$35.85 - $40.12 $ 47.3723%0
Richard Pzena 2014-03-31 Add 7.9%0.11%$35.85 - $40.12 $ 47.3723%6934282
George Soros 2014-03-31 Add 25.97%0.1%$35.85 - $40.12 $ 47.3723%1222181
Ray Dalio 2014-03-31 New Buy0.01%$35.85 - $40.12 $ 47.3723%17200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Abbott Laboratories

Lountzis Asset Management Comments on Abbott Laboratories - Mar 21, 2014

ABBOTT LABORATORIES (ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products.



On January 1, 2013, Abbott consummated the separation of its research based pharmaceuticals business and distributed 100% of the outstanding shares of common stock of AbbVie to the holders of record of Abbott common shares that were issued and outstanding on December 12, 2012. Each Abbot shareholder received one share of AbbVie common stock for every share of Abbot common stock held. The Abbott shareholder also received cash in lieu of any fractional share of AbbVie common stock resulting from the distribution.



Abbott common shares now trade under ticker symbol "ABT" and shares of AbbVie common stock trade under ticker symbol "ABBV". The new Abbott is a diversified global healthcare company with several leading franchises. In 2012, the company generated sales of $21.5 billion from these four diverse business units: nutritionals 30%, medical products 25%, established pharmaceuticals 24% and diagnostics 20%.



Abbott has leading market share positions in several businesses including the number one market share in:



1. Worldwide Adult Nutrition and U.S. Pediatric Nutrition



2. Amino Acid Immunoassay Diagnostics and Blood Screening



3. Drug Eluting Stents and for



4. Lasik



Furthermore, Abbott, in addition to a broad portfolio of products and services, is geographically diverse with 29% of sales in the U.S., 30% in other developed markets and 40% in the more rapidly growing emerging markets. The current Chairman and CEO, Miles D. White, will continue in these positions for the new Abbott, focused upon several initiatives including expanding the company’s products into new geographic markets, developing new technologies and focusing on accelerating margin expansion and improving free cash flow.



The new Abbott generated 2013 revenue through its four segments of $21.9 billion with earnings per share of $2.01. We continue to hold the new Abbott and believe its product and geographic diversity, combined with its leadership positions in several areas, will enable the company to continue to grow and prosper.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Diamond Hill Capital Comments on Abbott Laboratories - Jan 15, 2014

Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Abbott Laboratories

Diamond Hill Adds Two Companies to Portfolio in Third Quarter
At its web site, Diamond Hill Capital (Trades, Portfolio) Management calls itself “an independent investment management firm headquartered in Columbus, Ohio.” Read more...
Lountzis Asset Management Comments on Abbott Laboratories
ABBOTT LABORATORIES (ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 37.10
ABT's P/E(ttm) is ranked higher than
83% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 120.60 vs. ABT: 37.10 )
ABT' s 10-Year P/E(ttm) Range
Min: 5.76   Max: 37.31
Current: 37.1

5.76
37.31
Forward P/E 19.72
ABT's Forward P/E is ranked higher than
91% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABT: 19.72 )
N/A
PE(NRI) 34.60
ABT's PE(NRI) is ranked higher than
81% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 94.20 vs. ABT: 34.60 )
ABT' s 10-Year PE(NRI) Range
Min: 5.76   Max: 97.44
Current: 34.6

5.76
97.44
P/B 3.12
ABT's P/B is ranked higher than
77% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 4.16 vs. ABT: 3.12 )
ABT' s 10-Year P/B Range
Min: 1.39   Max: 3.13
Current: 3.12

1.39
3.13
P/S 3.16
ABT's P/S is ranked higher than
74% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 3.75 vs. ABT: 3.16 )
ABT' s 10-Year P/S Range
Min: 0.96   Max: 3.17
Current: 3.16

0.96
3.17
PFCF 24.67
ABT's PFCF is ranked higher than
91% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABT: 24.67 )
ABT' s 10-Year PFCF Range
Min: 4.38   Max: 30.6
Current: 24.67

4.38
30.6
POCF 17.94
ABT's POCF is ranked higher than
87% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 74.13 vs. ABT: 17.94 )
ABT' s 10-Year POCF Range
Min: 3.81   Max: 19.74
Current: 17.94

3.81
19.74
EV-to-EBIT 24.41
ABT's EV-to-EBIT is ranked higher than
83% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 68.02 vs. ABT: 24.41 )
ABT' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 32.4
Current: 24.41

6.7
32.4
Shiller P/E 15.74
ABT's Shiller P/E is ranked higher than
97% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABT: 15.74 )
ABT' s 10-Year Shiller P/E Range
Min: 8.21   Max: 15.82
Current: 15.74

8.21
15.82
Current Ratio 1.52
ABT's Current Ratio is ranked higher than
55% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. ABT: 1.52 )
ABT' s 10-Year Current Ratio Range
Min: 0.75   Max: 2.36
Current: 1.52

0.75
2.36
Quick Ratio 1.27
ABT's Quick Ratio is ranked higher than
60% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ABT: 1.27 )
ABT' s 10-Year Quick Ratio Range
Min: 0.55   Max: 2.07
Current: 1.27

0.55
2.07
Days Inventory 86.99
ABT's Days Inventory is ranked higher than
87% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 157.38 vs. ABT: 86.99 )
ABT' s 10-Year Days Inventory Range
Min: 76.02   Max: 131.57
Current: 86.99

76.02
131.57
Days Sales Outstanding 62.13
ABT's Days Sales Outstanding is ranked higher than
80% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 78.80 vs. ABT: 62.13 )
ABT' s 10-Year Days Sales Outstanding Range
Min: 54.72   Max: 129.28
Current: 62.13

54.72
129.28

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
ABT's Dividend Yield is ranked higher than
71% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. ABT: 1.90 )
ABT' s 10-Year Dividend Yield Range
Min: 1.41   Max: 7.9
Current: 1.9

1.41
7.9
Dividend Payout 0.63
ABT's Dividend Payout is ranked higher than
98% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABT: 0.63 )
ABT' s 10-Year Dividend Payout Range
Min: 0.23   Max: 2.53
Current: 0.63

0.23
2.53
Dividend growth (3y) -31.20
ABT's Dividend growth (3y) is ranked higher than
63% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. ABT: -31.20 )
ABT' s 10-Year Dividend growth (3y) Range
Min: -31.2   Max: 12.6
Current: -31.2

-31.2
12.6
Yield on cost (5-Year) 0.73
ABT's Yield on cost (5-Year) is ranked lower than
72% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 1.54 vs. ABT: 0.73 )
ABT' s 10-Year Yield on cost (5-Year) Range
Min: 0.55   Max: 3.06
Current: 0.73

0.55
3.06
Share Buyback Rate -0.40
ABT's Share Buyback Rate is ranked higher than
84% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -1.40 vs. ABT: -0.40 )
ABT' s 10-Year Share Buyback Rate Range
Min: 0.8   Max: -0.8
Current: -0.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.57
ABT's Price/Tangible Book is ranked higher than
63% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 6.96 vs. ABT: 10.57 )
ABT' s 10-Year Price/Tangible Book Range
Min: 3.1   Max: 427.6
Current: 10.57

3.1
427.6
Price/DCF (Projected) 1.00
ABT's Price/DCF (Projected) is ranked higher than
97% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABT: 1.00 )
ABT' s 10-Year Price/DCF (Projected) Range
Min: 0.36   Max: 1.93
Current: 1

0.36
1.93
Price/Median PS Value 1.98
ABT's Price/Median PS Value is ranked higher than
61% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. ABT: 1.98 )
ABT' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 1.75
Current: 1.98

0.63
1.75
Price/Graham Number 3.98
ABT's Price/Graham Number is ranked higher than
81% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABT: 3.98 )
ABT' s 10-Year Price/Graham Number Range
Min: 1.07   Max: 20.52
Current: 3.98

1.07
20.52
Earnings Yield (Greenblatt) 4.10
ABT's Earnings Yield (Greenblatt) is ranked higher than
82% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ABT: 4.10 )
ABT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 15
Current: 4.1

3.1
15
Forward Rate of Return (Yacktman) -14.50
ABT's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 5.08 vs. ABT: -14.50 )
ABT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -14.6   Max: 33.2
Current: -14.5

-14.6
33.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:ABT.UK, ABT.Switzerland, ABL.Germany, ABTT34.Brazil, ABT.Mexico, ABT.Argentina, ABT.Chile,
Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally.Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells f coronary, endovascular, structural heart, vessel closure and other medical device products.
» More Articles for ABT

Headlines

Articles On GuruFocus.com
AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
What Could Be The Major Highlights In AbbVie’s Upcoming Earnings Call? Jan 29 2015 
Feeling Good With This Med Company Jan 20 2015 
Diamond Hill Adds Two Companies to Portfolio in Third Quarter Dec 11 2014 
Boston Scientific Lost the First Place in Innovation Dec 11 2014 
Top 7 Dividend Aristocrats: The Best of The Best Dec 10 2014 
6 Stocks Giving Investors Potential Dividend Hikes In December Dec 04 2014 
Dividend Aristocrats In Focus Part 45: AbbVie Nov 24 2014 
Dividend Aristocrats In Focus Part 41: Abbott Laboratories (ABT) Nov 17 2014 
Sure Bets: Slow-Changing Industries for Long-Term Investors Oct 01 2014 


More From Other Websites
Mylan inversion deal completed Feb 27 2015
Interested In Pharmaceutical Stocks? Try Novartis (ADR) Feb 27 2015
Will Mylan (MYL) Beat Earnings on New Product Launches? - Analyst Blog Feb 27 2015
ABBOTT LABORATORIES Files SEC form 10-K, Annual Report Feb 27 2015
Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics... Feb 27 2015
Compelling Financial Benefit in Valeant's Latest Buy Feb 27 2015
Allergan: A new position for Glenview Capital Management Feb 25 2015
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis Feb 23 2015
Three Top Stocks Break Out As Market Stages Reversal Feb 20 2015
Abbott Declares 365th Consecutive Quarterly Dividend Feb 20 2015
D.E. Shaw ups its position in AbbVie Feb 20 2015
How to Build a Better Network at Work Feb 20 2015
Billionaire Bill Ackman’s Top Picks: Allergan Inc. (AGN), Air Products & Chemicals Inc. (APD),... Feb 19 2015
AbbVie Boosts Dividend 4% Feb 19 2015
Abbott to Present at Cowen and Company 35th Annual Health Care Conference Feb 19 2015
Time to Take Another Look at Oculus Innovative Sciences Feb 18 2015
5 Trade Ideas for Tuesday: Abbott Labs, Cheniere, Biomarin, Tractor Supply & Rockwell Automation Feb 16 2015
Zoetis Profit Up 20%, 2015 Outlook Cut Slightly Feb 11 2015
Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog Feb 11 2015
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog Feb 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK